BridgeBio Oncology Therapeutics, Inc. 8-K

What Happened

• BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an 8-K on June 22, 2026 reporting actions from its June 16, 2026 Annual Meeting. Michelle Doig resigned from the Board effective June 16, 2026 upon completion of her Class I director term; the resignation was not due to any disagreement with the company.
• At the same meeting the company’s stockholders elected two Class I directors and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Total shares entitled to vote: 80,112,725; shares present or represented by valid proxy: 48,344,441.
• Director elections:
  • Peter Lebowitz, M.D., Ph.D.: 31,822,504 votes FOR; 3,372 votes WITHHELD.
  • Frank P. McCormick, Ph.D., F.R.S., D. Sc.: 25,654,119 votes FOR; 6,171,757 votes WITHHELD.
  • There were 2,713,439 broker non-votes and 13,805,126 "no votes" reported with respect to the director elections.
• Auditor ratification:
  • Deloitte & Touche LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2026 with 34,535,875 votes FOR, 3,440 votes AGAINST and 0 abstentions.
  • The filing reports zero broker non‑votes and 13,805,126 "no votes" regarding the auditor ratification.

Why It Matters

• Board turnover and director elections affect corporate governance and oversight; investors watch director composition for signals about strategy, expertise, and board independence. Michelle Doig’s departure was a scheduled end-of-term resignation and not due to any reported disagreement.
• Ratifying Deloitte maintains continuity in the company’s external audit for 2026, which is relevant to financial reporting and investor confidence. The vote totals and the number of shares present vs. entitled to vote show that a substantial portion of shares were not represented at the meeting or recorded as "no votes," a factor investors may consider when assessing shareholder engagement.